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ABSTRACT: Aim: Eribulin mesylate is a synthetic analog of halichondrin B and is licensed 
for the treatment of patients with locally advanced or metastatic breast cancer that has 
progressed following treatment with anthracyclines and taxanes. It was not deemed 
to be cost effective based on a cost ana lysis by the National Institute for Health and Care 
Excellence in England and therefore it is not funded routinely by the National Health Service. 
The establishment of the Cancer Drugs Fund in England subsequently enabled access. As 
with any new chemotherapy drug that enters clinical practice for metastatic breast cancer 
(MBC) it is often used in heavily pretreated patients and the experience in a routine clinical 
setting can differ from that in a clinical study. We therefore present the experience of the first 
25 cases treated at our institution via the Cancer Drugs Fund. Materials & methods: A total 
of 25 patients were treated and in the 22 assessable cases the objective response rate was 
18% (four out of 22), with a clinical benefit rate of 41.0% (9 out of 22). Results: The median 
time-to-progression and overall survival were 4.08 months and 5.89 months, respectively. 
There was a significant difference in clinical benefit rate (odds ratio: 0.065; 95% CI: 0–0.529; 
p = 0.0055), as well as time-to-progression (hazard ratio: 9.18; 95% CI: 2.26–37.38; p = 0.002 
adjusted for age at diagnosis and interval between initial MBC diagnosis and commencing 
eribulin) favoring those patients who had not been rechallenged. There was no significant 
difference in overall survival (hazard ratio: 1.16; 95%  CI: 0.44–3.05; p  =  0.770 adjusted for 
age at diagnosis and interval between initial diagnosis of MBC and commencing eribulin). 
Conclusion: Eribulin mesylate shows clinical activity; however, there appears to be differences 
in terms of benefit in patients based on whether patients have been rechallenged with an 
anthracycline and/or a taxane. These data require confirmation in larger patient groups.
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Halichondrin B was the most potent of eight anti-tumor compounds derived from Halichondria 
okadai Kadota, a widely distributed black sea sponge found off the Pacific coast of Japan [1]. The 
initial cytotoxicity of the halichondrions and homohalicondrins was based on in vitro and in vivo 
studies of the melanoma cell line B-16 and leukemia cell lines P-388 and L-1210 [1]. Previously, 
okadaic acid, which is a potent inhibitor of serine/threonine PP1 and PP2A and itself cytotoxic, 
had been isolated from H. Okadai [2]. One of the major challenges in taking halichondrin B 
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forward as an anti-tumor drug was the very low 
amounts that could be derived from H. Okadai, 
with 600 kg of H. Okadai being required to 
produce the initial 12.5 mg of halichondrin B, 
as well as its complex structure of 32 stereocen-
ters [1]. However, the publication of a complete 
synthesis of halichondrin B [3], as well as the 
subsequent discovery that its biological activity 
resides in its macrocyclic lactone C1–C38 moi-
ety [4] led to the development of more structur-
ally simple, fully synthetic analogs that retain 
the biological activity of halichondrin B. The 
methodology for the synthesis of these analogs 
is patented by Eisai Pharmaceuticals (MA, USA) 
[5]. Over 180 such analogs were synthesized and 
tested, resulting in the identification of two 
macrocyclic ketone analogs of halichondrin B, 
named ER-076349 and ER-086526 [6], which 
were shown to have highly potent in vitro and 
in vivo anticancer activities. 
In vitro studies of ER-076349 and ER-086526 
demonstrated that they could inhibit growth 
at subnanomolar concentrations of several 
human cancer cell lines including breast cancer 
(MDA-MB-435), colon cancer (COLO 205 
and DLD-1) and prostate cancer (LNCaP and 
DU 145) with greater potency than vinblastine 
and paclitaxel [6]. Marked in vivo activities at 
doses of 0.1–1 mg/kg were observed for these 
two halichondrin analogs against four human 
xenografts: MDA-MB-435 breast cancer, 
COLO 205 colon cancer, LOX melanoma and 
NIH:OVCAR-3 ovarian cancer. ER-086526 
demonstrated superior efficacy at lower doses 
compared with paclitaxel [6], while in a pacli-
taxel-resistant human ovarian cancer cell line 
ER-086526 retained essentially complete 
in vitro activity [7].
ER-086526 (E7389 or NSC 707389) was 
taken forward for clinical development and later 
named as eribulin mesylate (herein referred to as 
eribulin). Eribulin binds to tubulin and inter-
feres with microtubule dynamics. It has a novel 
mechanism of action in that it predominantly 
inhibits microtubule growth, but not shorten-
ing, resulting in sequestration of tubulin into 
nonfunctional aggregates [8]. This is unlike other 
antimicrotubule agents such as vinca alkaloids 
and taxanes that suppress both the shortening 
and growth phases of microtubule dynamics. 
Eribulin interference with microtubular func-
tion leads to blockade of the G
2
–M phase of 
the cell cycle, disruption of mitotic spindles and 
apoptosis of tumor cells [6,8].
Phase I studies
Four Phase I studies have been performed. 
The first was performed with eribulin admin-
istered as a 1- to 2-min intravenous (iv.) bolus 
on days 1, 8 and 15 of a 28-day cycle at a dose of 
0.125–2.0 mg/m2 [9]; the same schedule was sub-
sequently used but with eribulin administered 
at a dose of 0.25–2.0 mg/m2 as a 1-h infusion 
[10]. In the third study, eribulin was adminis-
tered as a 1-h infusion every 21 days at a dose 
of 0.25–4 mg/m2 [11] and, following data from 
two initial Phase II studies [12,13], a fourth study 
with the eribulin administered over 2–10 min 
iv. on day 1 and 8 of a 21-day cycle at a dose of 
0.7–2.0 mg/m2 was performed [14]. In all of these 
studies neutropenia and/or febrile neutropenia 
were the most commonly reported dose-limiting 
toxicities (DLT). 
Eribulin on days 1, 8, and 15 of a 28-day cycle 
(1- to 2-min iv. bolus) at a dose of 2.0 mg/m2 
resulted in two DLTs (febrile neutropenia and 
neutropenia), and the maximum tolerated dose 
(MTD) was determined as 1.4 mg/m2 [9]. While 
eribulin, over an 1-h infusion according to the 
same treatment schedule as the first study at a 
dose of 1.4 mg/m2, resulted in two DLTs (two 
neutropenia and one of fatigue in one of these 
patients), in addition in three other patients 
neutropenia resulted in omission of cycle 1 
day 15 treatment. The MTD in this study was 
1.0 mg/m2 [10]. When administered every 21 days 
at a dose of 4 mg/m2, a DLT (febrile neutrope-
nia) was experienced by three patients on day 7 
[11]. At a reduced dose of 2.8 mg/m2 a further 
two patients experienced the same DLT, and the 
MTD was subsequently determined to be 2 mg/
m2 [11]. Eribulin given on days 1 and 8 every 
21 days resulted in three DLTs (neutropenia) at 
2.0 mg/m2, and the MTD was determined to 
be 1.4 mg/m2 [14]. At a dose of 1.4 mg/mg2 on 
days 1 and 8 every 21 days the median time from 
day 1 to nadir in neutrophil count was 14 days 
for eribulin 1.4 mg/m2 (range: 11–14 days), in 
patients who received only their day 1 dose [14]. 
The median time to recovery from the nadir to 
grades 0 or 1 was 8 days for patients receiving 
eribulin on both days 1 and 8 [14]. Observed non-
hematological toxicities included hypoglycemia, 
hypophosphatemia and fatigue [9], peripheral 
neuropathy [10,14], and elevated g-glutamyltrans-
ferase (liver metastasis) [14]. Fatigue and alopecia 
were also reported across the studies.
Pharmacokinetic ana lysis demonstrated that 
eribulin displayed linear kinetics over the dose 
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range studied, that it had a high volume of distri-
bution, and a rapid distribution phase followed by 
a slow elimination phase [9–11,14]. Urinary excre-
tion of eribulin is minimal with 5–13% of the 
administered dose eliminated in urine [10,11,14]. 
A subsequent study utilizing 14C-eribulin found 
that eribulin undergoes limited metabolism and 
confirmed the minimal excretion of eribulin in 
the urine. The predominant route of elimination 
is primarily in the feces [15].
Given that hepatic involvement in malignant 
disease is common and can affect hepatic func-
tion and, therefore, the handling and excretion 
of drugs, a Phase I study was also performed to 
determine the pharmacokinetics of eribulin in 
patients with solid tumors and hepatic impair-
ment, with the objective of defining the safety of 
eribulin in such patients [16]. In total, 18 patients 
were recruited, six with normal hepatic func-
tion, seven with Child–Pugh A and five with 
Child–Pugh B group hepatic impairment. Erib-
ulin was given on day 1 and 8 of a 21-day cycle 
at a dose of 1.4, 1.1 and 0.7 mg/m2 for normal, 
Child–Pugh A and Child–Pugh B patients, 
respectively. Although the dose could be esca-
lated in those starting on lower doses this did not 
happen in any cases. Hepatic impairment was 
found to increase the exposure to eribulin, with 
the mean dose-normalized area under the curve 
increased by 1.75-fold (90% CI: 1.16–2.65) 
in those with Child–Pugh A and 2.48-fold 
(90% CI: 1.57–3.92) in Child–Pugh B as com-
pared with patients with normal hepatic func-
tion [16]. Hepatic impairment also decreased 
clearance and prolonged elimination half-life 
of eribulin. The underlying reason for the 
increased exposure with eribulin in patients with 
hepatic dysfunction is reduced biliary excre-
tion, as a result of reduced biliary flow, as well 
as reduction in transporter-mediated excretion 
in the bile. This study supports routine dose 
reduction in patients with Child–Pugh A or B 
hepatic impairment who are to receive eribulin.
Phase II studies
Eribulin has been tested in a number of Phase II 
studies in locally advanced and metastatic breast 
cancer (MBC) [12,17–20], as well as a feasibility 
study in the adjuvant setting [21]. The initial 
Phase II studies explored the efficacy of eribu-
lin in a heavily pretreated population that had 
received a median of three to four prior che-
motherapy regimens [12,17,18]. Subsequently, it 
has been tested as first-line therapy for locally 
recurrent or MBC in both HER2-negative [19] 
and HER2-positive disease where it was com-
bined with trastuzumab [20]. Table 1 summarizes 
these Phase II studies.
In the two initial Phase II studies, one in 
MBC and the other in non-small-cell lung can-
cer, a dose of 1.4 mg/m2 as a 2–5-min iv. infu-
sion on days 1, 8, and 15 of a 28-day cycle was 
selected [12,13]. However, 63% of patients (44 
out of 70) experienced dose delays associated 
with neutropenia during the first cycle, result-
ing in omission of the day 15 dose. Therefore, 
the schedule was modified to day 1 and 8 of a 
21-day cycle [12]. Similarly, in the non-small-
cell lung cancer Phase II study, hematological 
toxicities resulted in dose interruptions, delays, 
or omissions when eribulin mesylate 1.4 mg/m2 
was administered on days 1, 8 and 15 of a 28-day 
cycle. The dosing schedule was again changed to 
days 1 and 8 of a 21-day cycle [13]. Given that a 
formal Phase I study had not been undertaken to 
determine the optimal dose for eribulin mesylate 
when administered on days 1 and 8 of a 21-day 
cycle a fourth Phase I study was established [14].
This determined that 1.4 mg/m2 administered 
on days 1 and 8, of a 21-day cycle was the MTD; 
this was the dosing regimen taken forward in all 
subsequent studies. 
Feasibility study for adjuvant trial
As well as these Phase II studies a feasibility 
study is currently examining eribulin as adju-
vant therapy following dose-dense doxorubicin 
(A) and cyclophosphamide (C) in patients with 
early-stage breast cancer. Treatment consists of 
dose-dense AC (A: 60 mg/m2 iv.; C: 600 mg/m2 
iv.) on day 1 of each 14-day cycle for four cycles, 
followed by eribulin 1.4 mg/m2 iv. over 2–5 min 
on days 1 and 8 every 21 days for four cycles 
[21]. The primary objective was the ability to 
complete four cycles of eribulin without a treat-
ment-related dose delay (defined as >2 days) or 
reduction. The study is deemed feasible if 56 or 
more of the 80 patients can complete the eribu-
lin portion of the study. Exploratory end points 
include safety, 3-year disease-free survival and 
overall survival (OS). To date, 55 of 80 patients 
have been recruited with 46 evaluable for feasi-
bility. The current feasibility rate is 70% (32 out 
of 46), with neutropenia being the issue affect-
ing feasibility. However, with administration of 
growth factor treatment this increased to 85% 
(39 out of 46). Given the initial issue with neu-
tropenia the study is being amended to include 
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a second cohort that will utilize regimented 
granulocyte colony-stimulating factor [21].
Phase III studies
Two Phase III studies have been performed that 
have tested the efficacy of eribulin in MBC. 
The first was the EMBRACE study, which 
was a Phase III open-label study of women 
with locally recurrent breast cancer or MBC 
that compared eribulin to a treatment of physi-
cian’s choice (TPC) [22]. Eribulin was given at 
1.4 mg/m2 as a 2–5 min iv. infusion on days 1 
and 8 of a 21-day cycle. In total, 762 women 
were enrolled and had received between two 
and five previous chemotherapy regimens, with 
two or more for advanced disease; these had to 
include an anthracycline and a taxane, unless 
contraindicated. The primary end point was 
OS, and secondary end points included pro-
gression-free survival (PFS), objective response 
rate (ORR) and duration of response. OS was 
significantly improved in the eribulin group 
(median: 13.1 months; 95% CI: 11.8–14.3) 
compared with the TPC group range (median: 
10.6 months; 9.3–12.5; hazard ratio [HR] 0.81; 
95% CI: 0.66–0.99; p = 0.041). Median PFS 
was 3.7 months (95% CI: 3.3–3.9) with eribulin 
and 2.2 months (95% CI: 2.1–3.4) with TPC 
(HR: 0.87; 95% CI: 0.71–1.05; p = 0.137), while 
the response rate was 12% (95% CI: 9.4–15.5) 
for eribulin versus 5% (95% CI: 2.3–8.4; 
p = 0.002) for TPC. Significant grade 3/4 toxici-
ties associated with eribulin were asthenia (9%), 
neutropenia (45%) and peripheral neuropathy 
(9%). The most common side effect leading to 
eribulin discontinuation was peripheral neurop-
athy (5% of patients). The mean time to nadir 
within a cycle was approximately 13 days, and 
mean time to recovery to grade 2 or lower was 
approximately 8 days [22].
A second randomized Phase III study of 
1102 patients with locally advanced disease 
or MBC who have received up to three prior 
chemotherapy regimens (including an anthra-
cycline and a taxane) compared the efficacy 
and safety of eribulin (1.4 mg/m2 as a 2–5 min 
iv. infusion on days 1 and 8 of a 21-day cycle) 
versus capecitabine (1250 mg/m2 twice daily on 
days 1–14 every 21 days) [23]. The coprimary 
end points of this study were OS and PFS, 
and secondary end points were: ORR; quality 
of life; duration of response; 1-, 2- and 3-year 
survival; and safety. In the study 27% received 
study treatment as first-line therapy while 57.4 
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and 14.7% received it as second- and third-line 
treatment, respectively.
Median OS was 15.9 and 14.5 months (HR: 
0.879; 95% CI: 0.770–1.003; p = 0.056), 
for eribulin and capecitabine, respectively 
[23]. OS at 1 year was 64.4% for eribulin ver-
sus 58.8% for capecitabine (p = 0.035); at 
2 years was 32.8% for eribulin versus 29.8% 
for capecitabine (p = 0.324); and at 3 years 
was 17.8% for eribulin versus 14.5% for 
capecitabine (p = 0.175). PFS (independent 
review) was 4.1 and 4.2 months (HR: 1.079; 
95% CI: 0.932–1.250; p = 0.305) for eribulin 
and capecitabine, respectively. ORR (indepen-
dent review) was 11.0 (95% CI: 8.5–13.9) and 
11.5% (95% CI: 8.9–14.5; p = 0.849), respec-
tively [23]. The median number of treatment 
cycles was six for eribulin (range: 1–65) and 
five for capecitabine (0–61), while the duration 
of treatment was 4.1 months for eribulin (range: 
0.7–45.1) and 3.9 months for capecitabine 
(0.7–47). Prespecified subgroup ana lysis sug-
gested that some subgroups may derive greater 
benefit with regard to OS with eribulin. These 
included HER2-negative (15.9 months for 
eribulin and 13.5 months for capecitabine; HR: 
0.838; 95% CI: 0.715–0.983; p = 0.030), estro-
gen receptor-negative (14.4 months for eribulin 
and 10.5 months for capecitabine; HR: 0.779; 
95% CI: 0.635–0.955) and triple-negative 
(14.4 months for eribulin and 9.4 months for 
capecitabine; HR: 0.702; 95% CI: 0.545–0.906) 
breast cancers.
With regard to adverse effects (all grades) 
hematological toxicities were much more 
common with eribulin as compared with 
capecitabine; neutropenia was seen in 54 ver-
sus 16% and leukopenia in 31.4 versus 10.4%. 
However, febrile neutropenia was low (2 vs 
<1%). Nonhematological toxicities were con-
sistent with known data for both agents with 
capecitabine having a higher rate of hand–foot 
syndrome (0.2% eribulin vs 45.1% capecitabine) 
and diarrhea (14.3 vs 28.8%), and eribulin caus-
ing more peripheral neuropathy (13 vs 7%) and 
alopecia (35 vs 4%) [23]. This study establishes 
that eribulin and capecitabine have similar effi-
cacy in a heterogeneous population of patients 
with regard to line of treatment and subtype of 
breast cancer.
Based on the EMBRACE data, eribulin was 
approved by the US FDA in November 2010, 
and was subsequently approved in Europe in 
March 2011 [24] for the treatment of patients 
with locally advanced or recurrent breast cancer 
that had progressed after two lines of chemo-
therapy; prior therapy has to include an anthra-
cycline and taxane unless deemed unsuitable for 
these patients. Within England all new cancer 
agents are considered by the National Institute 
for Health and Care Excellence (NICE) and in 
Scotland by the Scottish Medicine Consortium 
Table 2. Clinicopathological characteristics.
Characteristic Patients (n) 
Total patients (n) 25
Median age; years (range) 58 (28–81)
Median time since diagnosis of 
MBC to commencing eribulin; 
months (range)
32 (2–92)
Hormone receptor status on diagnosis of MBC; 
n (%)
ER+, PgR+, HER2+ 4 (16)
ER+, PgR-, HER2+ 2 (8)
ER-, PgR-, HER2+ 2 (8)
ER+, PgR+, HER2- 8 (32)
ER+, PgR-, HER2- 4 (16)
ER-, PgR-, HER2- 5 (20)
(Neo)adjuvant chemotherapy; n (%) 
FEC 3 (12)
FEC-T 11 (44)
CMF 1 (4)
EC 1 (4)
MC 1 (4)
Trastuzumab 1 (4)
None/not applicable 8 (32)
Adjuvant endocrine therapy
Tamoxifen 9 (36)
Goserelin + tamoxifen 2 (8)
Tamoxifen–exemestane 1 (4)
Anastrozole/letrozole 4 (16)
None/not applicable (ER-/de novo 
metastatic disease)
9 (36)
De novo metastatic disease; n (%)
De novo metastatic disease 5 (20)
Site of distant metastases; n (%)
Bone 13 (52)
Liver 15 (60)
Lung 15 (60)
Brain 4 (16)
Adrenal 2 (8)
CMF: Cyclophosphamide, methotrexate and 5-fluorouracil; 
EC: Epirubicin and cyclophosphamide; ER: Estrogen receptor; 
FEC: 5-fluorouracil, epirubicin and cyclophosphamide; 
FEC-T: 5-fluorouracil, epirubicin and cyclophosphamide plus 
docetaxel; MBC: Metastatic breast cancer; MC: Non-PEGylated 
liposomal doxorubicin and cyclophosphamide; 
PgR: Progesterone receptor.
Future Oncol. (2014) 10(3)368
Activity of eribulin mesylate in heavily pretreated breast cancer RESEARCH ARTICLE
future science group www.futuremedicine.com
for funding approval prior to use within the 
licensed indication. NICE considered that the 
incremental cost–effectiveness ratios for eribulin 
versus TPC within the EMBRACE population 
was at least GB£68,000 per quality-adjusted life 
year gained and, therefore, did not recommend 
its funding [25]. The Scottish Medicine Consor-
tium calculated that compared with TPC the 
cost per quality-adjusted life year was GB£81,852 
for eribulin [26] and, therefore, again did not 
recommended its funding and use. The issue of 
accessing and funding high-cost drugs led to the 
establishment of the Cancer Drugs Fund (CDF) 
for drugs not funded by NICE in October 2010 
[27]. The CDF applies solely to England. Drugs 
and how they were accessed was initially deter-
mined regionally via a clinically led panel, but in 
April 2013 a national CDF list was established 
[28]. Eribulin has been available in London via 
the CDF since September 2011 [29]. To be eligi-
ble patients have to have locally advanced breast 
cancer or MBC that has progressed after at least 
two chemotherapeutic regimens for advanced 
disease. Prior therapy should have included an 
anthracycline and a taxane unless patients were 
not suitable for these treatments. 
Materials & methods
All requests for eribulin to the London CDF 
between the 29 September 2011 and 28 Feb-
ruary 2013 for patients with locally advanced 
breast cancer or MBC attending Imperial Col-
lege Healthcare NHS Trust (London, UK) were 
reviewed. Patients commencing on treatment 
were identified and their case notes and radiol-
ogy reviewed. To be eligible for eribulin via the 
CDF patients had to meet the criteria previously 
described above. The histopathological and 
(neo)adjuvant treatment details, site of disease 
when commencing eribulin, prior metastatic 
treatment including rechallenging with anthra-
cyclines or taxanes, number of cycles of eribulin, 
time-to-progression (TTP), best response and 
outcome, as well as any treatment given after 
completing eribulin, were recorded. All patients 
commenced on eribulin 1.23 mg/m2 (equivalent 
to 1.4 mg/m2 eribulin mesylate) iv. on days 1 
and 8 of every 21-day cycle, unless otherwise 
stated.
TTP was defined as time from first eribulin 
treatment to date of progression (including pro-
gression-related death) with death from other 
causes and withdrawal as censoring events. OS 
was defined as time from first eribulin treatment 
to death from any cause with censoring events, 
such as alive on last follow-up examination. 
Follow-up was administratively censored on 
Table 3. Breast cancer treatment received in 
metastatic setting prior to and following 
eribulin.
Treatment Patients (n)
Endocrine therapy
Tamoxifen 2
AI alone 18
AI + FEC chemotherapy 2
AI + trastuzumab 1
Fulvestrant 8
Steroid sulfatase inhibitor 2
Goserelin alone 1
Goserelin + AI 1
Goserelin + AI + trastuzumab 1
Median lines of prior endocrine 
therapy for MBC (range)
1 (0–5)
Chemotherapy 
Capecitabine alone 20
Capecitabine/lapatinib 4
Capecitabine/trastuzumab 1
Paclitaxel 16
Docetaxel 3
Docetaxel/carboplatin 1
FEC 5
FEC-T 1
MC 4
Vinorelbine 3
Gemcitabine/carboplatin 1
CMF 1
Paclitaxel/trastuzumab 1
Docetaxel/trastuzumab 2
FEC/trastuzumab 1
Median lines of prior chemotherapy 
for MBC (range)
3 (1–4)
Median lines of prior chemotherapy 
(Adj and MBC) (range)
3 (2–5)
Treatment for metastatic breast cancer after 
eribulin (n = 11)
Vinorelbine 6
Epirubicin 1
Nab-paclitaxel 1
Paclitaxel 1
MC 1
Gemcitabine/carboplatin 1
Adj: Adjuvant; AI: Aromatase inhibitors; 
CMF: Cyclophosphamide, methotrexate and fluorouracil; 
FEC: 5-fluorouracil, epirubicin and cyclophosphamide; 
FEC-T: 5-fluorouracil, epirubicin and cyclophosphamide plus 
docetaxel; MBC: Metastatic breast cancer; MC: Non-PEGylated 
liposomal doxorubicin and cyclophosphamide.
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28 February 2013. Survival analyses used the 
Kaplan–Meier method and Cox’s proportional 
hazards model. Exact confidence limits were 
calculated for binomial proportions, with cal-
culations performed in Statav 12.1 (StataCorp, 
TX, USA).
Response evaluation criteria in solid tumors 
was used to define response [30] and adverse 
events and laboratory abnormalities were graded 
according to the National Cancer Institute 
Common Terminology Criteria for Adverse 
Events, version 3.0 [31]. ORR was defined as the 
rate of complete response or partial response; 
while clinical benefit rate (CBR) was defined as 
the rate of complete plus partial response plus 
stable disease of at least 6 months’ duration.
Results
Twenty-five patients were treated via the Lon-
don CDF with eribulin between September 2011 
and February 2013. Baseline characteristics of 
patients and treatments prior to and following 
eribulin therapy are summarized in Tables 2 & 3, 
respectively. 
In those assessable, the ORR was 18% (four 
out of 22; 95% CI: 5.2–40.3%). Three patients 
did not undergo midtreatment assessment: one 
died suddenly after the first cycle, the cause of 
which is unknown, and another two patients dis-
continued secondary to toxicity prior to assess-
ment (Table 4). The CBR was 41% (nine out of 
22; 95% CI: 21.0–64.0), the overall median 
TTP was 4.08 months (95% CI: 2.40–8.95) 
and the median OS was 5.89 months (95% CI: 
3.88–8.75) (Figure 1). Five patients remain on 
treatment at time of ana lysis, with 55% (11 
out of 20) having gone on to receive further 
chemotherapy at disease progression (Table 3). 
In total, 44% (11 out of 25) of patients had 
been rechallenged with an anthracycline or tax-
ane during their disease course prior to eribulin. 
In those assessable, when the response to treat-
ment was compared based on rechallenge there 
was a numerical but nonsignificant difference 
in ORR favoring those not rechallenged of 28.5 
(four out of 14) versus 0% (zero out of eight), 
respectively (p = 0.254), but there was a signifi-
cant difference in CBR of 64 (nine out of 14) 
versus 0% (zero out of eight; p = 0.0055). TTP 
was significantly longer in those not rechallenged; 
median TTP was 8.95 versus 2.60 months (HR: 
9.18; 95% CI: 2.26–37.38; p = 0.002); while OS 
was numerically longer in those rechallenged, the 
difference was not statistically significant: median 
OS was 6.94 versus 3.82 months (HR: 1.16; 95% 
CI: 0.44–3.05; p = 0.770) (Figure 2).
Of note, one patient received eribulin con-
currently with trastuzumab with no problems. 
In one case eribulin was given at 0.7 mg/m2 due 
to severely deranged liver function tests due to 
metastatic disease. However, a grade 3 asym-
metrical, sensorimotor polyneuropathy developed 
that led to cessation of eribulin; this subsequently 
improved. Despite discontinuing after 1.5 cycles 
there was clear evidence of clinical and biochemi-
cal improvement, as evidenced by improving liver 
function tests and a fall in CA153 from 687 to 
397 kunits/l. A scan subsequently performed for 
clinical reasons showed evidence consistent with 
stable disease. Neutropenia and neurotoxicity 
were the most common toxicities, and the major-
ity were grade 1 and 2 (Table 4).
Discussion
Chemotherapy is a key treatment in the manage-
ment of endocrine refractory estrogen receptor-
positive breast cancer as well as the treatment 
of choice in triple-negative breast cancer. In 
Table 4. Details of eribulin treatment, 
response and toxicity.
Characteristic Patients (n)
Median number of cycles of eribulin, 
n (range)
4 (1–15)
Response; n (%)
Complete response 0 (0)
Partial response 4 (16)
Stable disease 8 (32)
Progressive disease 10 (40)
Clinical benefit rate 9 (41)
Not assessable 3 (12)
Toxicity; n (%)
None 9 (36)
Neuropathy; n (%)
Grade 1 3 (12)
Grade 2 1 (4)
Grade 3 1 (4)
Neutropenia; n (%)
Grade 1 5 (20)
Grade 2 3 (12)
Other
Nausea/vomiting (grade 1) 3 (12)
Diarrhea (grade 1) 1 (4)
Fatigue (grade 2) 2 (8)
Abnormal liver function tests 1 (4)
Clinical benefit rate included complete or partial response, or 
stable disease of at least 6-month duration. 
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HER2-positive breast cancer chemotherapy is 
a key backbone with which HER2-based ther-
apy is combined either as separate agents given 
concurrently [32] or, more recently, the use of 
chemotherapy conjugated to a HER2 antibody 
[33]. The potential chemotherapeutic options for 
patients requiring chemo therapy for MBC include 
anthracycline-based regimens [34]; taxane-based 
therapy, either as a single agent or combined with 
capecitabine [35] or bevacizumab [36,37]; single-
agent capecitabine [38] or capecitabine combined 
with ixabepilone [39] or bevacizumab [40]; plati-
num-based treatments [41]; vinorelbine with or 
without gemcitabine [42,43]; and a cyclophospha-
mide, methotrexate and 5-fluorouracil combina-
tion [44]. For those with prior anthracycline and 
taxane exposure, rechallenging is also an option 
[45]; and in HER2-positive disease trastuzumab 
[32], lapatinib [46], pertuzumab [47] and T-DM1 [33] 
are also options. Eribulin, therefore, joins a large 
list of potential therapeutic options; based on cur-
rent data it is a treatment option for patients who 
have been previously exposed to an anthracycline, 
a taxane and capecitabine [22], and recent data in 
a more heterogeneous group have shown it is an 
alternative treatment option to capecitabine [23]. 
In this unselected cohort of patients all but two 
had prior treatment with an anthracycline, a tax-
ane and capecitabine. One case was not treated 
with an anthracycline due to prior exposure dur-
ing treatment for non-Hodgkin’s lymphoma, and 
one patient had not received capecitabine prior to 
eribulin. In those patients who were assessable the 
ORR was 18% (four out of 22), while the TTP 
for the whole cohort was 4.1 months. While it 
is clearly difficult to compare across this study 
and a randomized study [22], the ORR and TTP 
are comparable to the data within EMBRACE. 
However, the OS is shorter in our patient group: 
5.9 versus 13.1 months within EMBRACE. The 
difference in OS may be explained by the prior 
treatment received before the eribulin, with 96% 
(24 out of 25) in the current study having been 
exposed to capecitabine prior to eribulin as com-
pared with 74% in EMBRACE. Therefore, the 
potential to use an agent with known efficacy 
was much more limited in our patients follow-
ing progression. However, the similar ORR and 
TTP between the current cohort and those within 
EMBRACE suggests that eribulin is still effective 
in a patient population that has been exposed to 
capecitabine. Furthermore, 44% of cases in the 
current cohort had been rechallenged with an 
anthracycline or a taxane and it is not clear from 
the EMBRACE study what proportion of those 
that received eribulin did so following rechal-
lenging with these agents. The presence within 
this current cohort of a high proportion of such 
patients could have impacted the OS data. Within 
EMBRACE, 50% of patients randomized to 
eribulin went onto receive further chemotherapy 
postprogression, as compared with 44% of cases 
within this cohort. The difference seen in OS 
may be a reflection of this, as well as the relative 
efficacy of postprogression treatment in the two 
cohorts.
In those progressing on eribulin, 55% (11 out 
of 20) received further chemotherapy, the major-
ity receiving the alternative antimicrotubule agent 
vinorelbine. The degree of crossresistance between 
vinorelbine and eribulin is unknown, as is the effi-
cacy. Four of the remaining five were rechallenged 
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Figure 1. Progression-free survival and overall survival for the whole of the treated cohort. (A) Progression-free survival and 
(B) overall survival.
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with an anthracycline or taxane; again, potential 
efficacy of such a treatment is unclear [45]. In 
total, 50% of eribulin-treated patients within 
EMBRACE received further chemotherapy 
postprogression, although the treatment regimens 
used in these cases are not available [22]. Such data, 
as well as the efficacy of this postprogression 
treatment, would clearly be of value to support 
and guide systemic treatment decisions beyond 
eribulin. With regard to the difference seen in 
OS between the EMBRACE population and this 
cohort it may be a reflection of the proportion 
who received subsequent treatment as well as the 
relative efficacy of this postprogression treatment.
In total, 44% (11 out of 25) of the cohort had 
been re-exposed to either an anthracycline or a 
taxane during their adjuvant and/or metastatic 
treatment, and all had received capecitabine. 
There was a significant difference in CBR and 
TTP compared with those not rechallenged: 
while OS was numerically longer it was not sta-
tistically significant. The reasons for these differ-
ences may be due to the number of lines of prior 
treatment, which was higher in the rechallenged 
group as compared with those not rechallenged, 
with a median of four and three cycles of prior 
chemotherapy, respectively (Table 5). In addition, 
the reutilization of key classes of chemotherapy 
agents could be indicative of disease that is rela-
tively refractory or that has exhausted reasonable 
treatment options. Furthermore, the potential 
effects on re-exposing a tumor to the same class 
of agents on subsequent treatments is unclear: this 
may be particularly important in those rechal-
lenged with a taxane given the mechanism of 
action of eribulin. This observation is hypothesis 
generating given the small numbers and retro-
spective nature of the study. However, the ben-
efit of eribulin based on rechallenging should be 
explored with the EMBRACE data set [22]. Such 
data are important as it may identify patients who 
are less likely to derive benefit from eribulin; this 
is particularly important in MBC given the incur-
able nature of the disease and the importance of 
quality of life.
Eribulin was well tolerated in this cohort of 
heavily pretreated patients with the majority of 
toxicities being grade 1 and 2, and, as expected, 
neutropenia and neurotoxicity were the most 
common. The case of grade 3 neurotoxicity was 
in a patient with severely deranged liver function 
tests who was treated with the recommended dose 
of 0.7 mg/m2. It is known that liver dysfunction 
can significantly increase the exposure to eribu-
lin by 1.75- to 2.48-fold [14], and that caution is, 
therefore, required in such cases. 
The current dose modifications for eribulin 
where there is liver dysfunction is based on the 
Child–Pugh score [16]. However, the Child–Pugh 
score was developed to assess the operative risk in 
patients requiring surgical portosystemic shunts 
due to chronic liver disease [48], with the score 
representing the collective knowledge of surgeons 
accumulated over time performing this proce-
dure. It was subsequently modified by Pugh and 
colleagues to describe the outcome of patients 
undergoing surgical ligation of esophageal vari-
ces due to chronic liver disease [49]. Hence, the 
Child–Pugh Score was developed for a specific 
prognostic purpose, and was not developed for or 
intended to be used in the dosing of drugs that 
may be metabolized or excreted via the liver. 
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N: Not rechallenged; Y: Rechallenged with anthracycline and/or taxane.
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Ordinarily, within oncology, both trial entry 
and dose modifications for such drugs have been 
based on the degree of derangement of the liver 
function tests (namely transaminases and alkaline 
phosphatase) from the upper limit of normal [17]. 
Given the data that even at the lower dose using 
the Child–Pugh score there is a significant effect 
on eribulin exposure [50], and given the fact that 
the Child–Pugh score was not developed for this 
purpose, consideration should be given to further 
pharmacokinetics studies that are based on liver 
function as measured by transaminases and alka-
line phosphatase. This would be helpful in clarify-
ing if a lower dose or modified treatment regimen 
could reduce the eribulin exposure and, there-
fore, reduce the risks of eribulin accumulation 
and, therefore, associated toxicity in such cases. 
Furthermore this would be helpful in developing 
more relevant dose modification criteria. This is 
particularly important given the palliative nature 
of the treatment and the need to avoid unneces-
sary toxicity with its potential affects on quality 
of life, as well as ensuring that the drug is not 
unnecessarily discontinued.
One sudden unexplained death after the first 
treatment was observed, and its link to eribulin 
is unknown. There are no previous reports in the 
literature of sudden deaths with eribulin and it is 
not possible to establish any causal link between 
the death and eribulin treatment. In an open-label 
ECG study of 26 patients eribulin was found to 
cause QT prolongation on day 8, independent of 
eribulin concentration, with no QT prolongation 
observed on day 1 [50]. Therefore, ECG monitoring 
is recommended if therapy is initiated in patients 
with bradyarrhythmia, electrolyte abnormalities, 
or concomitantly to drugs that prolong the QT 
interval, as well as avoidance of use in congenital 
long-QT syndrome. To the best of our knowledge 
this patient had no prior cardiac history, nor were 
they receiving any concomitant medications. 
In conclusion, in the setting of a routine clinical 
practice involving heavily pretreated patients erib-
ulin has evidence of clinical activity and is well tol-
erated. Of interest, a comparison of patients based 
on a history of rechallenging either with anthra-
cyclines or taxanes appears to suggest that these 
patients with no such history may derive greater 
benefit from eribulin. This requires confirmation 
in a larger data set.
Conclusion & future perspective
Eribulin is now established as a therapeutic 
option in women who have been previously 
exposed to an anthracycline and taxane [22] and, 
in a heterogeneous population, has recently 
been shown to be equivalent to capecitabine 
[23]. Studies are currently investigating its effi-
cacy as a first-line agent in both HER2-negative 
and -positive disease. Furthermore, its feasi-
bility in a potential adjuvant regimen is being 
explored. Taxanes are currently the most widely 
used antimicrotubule agents in the treatment of 
breast cancer. However, paclitaxel and docetaxel, 
formulated in Cremophor® EL (BASF Corp., 
Ludwigshafen, Germany) and polysorbate 80, 
respectively, are diluents associated with hyper-
sensitivity reaction that necessitate premedica-
tion with steroids. Furthermore, paclitaxel and 
docetaxel require polyethylene-lined rather than 
PVC sets given the associated leeching of plas-
ticizer di-(2-ethylhexyl) phthalate that occurs 
with PVC infusion sets. Given the water soluble 
nature of eribulin it does not require premedica-
tion or particular infusion sets and is not associ-
ated with infusion reactions, it also has a shorter 
infusion time. Therefore, eribulin represents an 
alternative nontaxane antimicrotubular agent; 
however, formal studies are required to assess its 
relative efficacy to these agents. Recent subgroup 
ana lysis from the comparative study of eribu-
lin versus capecitabine suggests certain groups 
may derive particular benefit from eribulin [23]; 
this again requires formal testing in the context 
of clinical studies. With regard to subsequent 
treatments following eribulin, information is 
needed regarding the response and toxicities 
to such treatments. This is important to guide 
subsequent decision-making and is particularly 
relevant to other antimicrotubule agents such as 
vinorelbine and ixabepilone. To date, Phase III 
data with eribulin have been in the context of 
a single agent [22,23] and one Phase II study has 
explored it in sequence with AC chemotherapy 
[21]. However, its efficacy may be improved by 
combining it with other chemotherapy agents, 
such as HER2-directed or antiangiogenesis 
agents. Such combination treatments, particu-
larly with chemotherapy, will probably require 
modification to the dose and/or regimen. 
Table 5. Median lines of chemotherapy in patients rechallenged versus not 
rechallenged with anthracycline or taxane in the metastatic setting.
Median lines of chemotherapy Rechallenged with anthracycline or taxane
Yes (n = 11) No (n = 14)
Adjuvant and metastatic (range) 4 (3–5) 3 (2–4)
Metastatic only (range) 3 (2–4) 3 (1–3)
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EXECUTIVE SUMMARY
Background
 ● Eribulin mesylate is a synthetic analog of halichondrin B, a naturally occurring product isolated from Halichondria 
okadai.
 ● Eribulin is an inhibitor of microtubule dynamics.
 ● Hepatic impairment decreases the clearance of eribulin.
 ● The EMBRACE study showed that eribulin as compared with treatment of physician’s choice resulted in a significant 
increase in overall survival in heavily pretreated locally advanced disease/metastatic breast cancer.
 ● Eribulin is equivalent to capecitabine in locally advanced disease/metastatic breast cancer that has been exposed to 
up to three prior chemotherapy regimens.
 ● The most common toxicities are neutropenia, fatigue, alopecia and peripheral neuropathy.
 ● It has not been deemed to be a cost-effective treatment in the UK.
 ● In England eribulin can be accessed via the Cancer Drugs Fund. 
Results
 ● In 25 women receiving treatment via the Cancer Drugs Fund the objective response rate was 18% and the clinical 
benefit rate was 55%.
 ● The median time to progression was 4.08 months and overall survival was 5.89 months.
 ● Clinical benefit rate and time to progression were significantly longer in those patients who had not been 
rechallenged with an anthracycline or taxane.
 ● Treatment was well tolerated.
 ● One case of neurotoxicity on the background of deranged liver function tests (LFTs) was recorded despite a dose 
reduction to the lowest dose. This resolved on discontinuation of the drug.
 ● One sudden unexplained death was recorded.
Conclusion 
 ● The use of eribulin in a routine clinical practice in a heavily pretreated population does result in clinical benefit and 
overall is well tolerated.
 ● Caution is required in patients with deranged LFTs even when using the recommend 0.7 mg/m2 dose. Studies of 
alternative doses or regimens of eribulin are required in patients with severely deranged LFTs.
 ● A comparison of patients based on a history of rechallenging either to anthracyclines or taxanes appears to suggest 
that these patients with no such history may derive greater benefit from eribulin. This requires confirmation in a 
larger data set.
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